In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 15 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Mortality predictors, in the first 24 hours, in patients admitted in Non-cardiac Intensive Care Unit with Cardiogenic Shock

Session Poster Session 1

Speaker Hugo Miranda

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : H Miranda (Lisbon,PT), I Milet (Vila Real,PT), N Barros (Vila Real,PT), H Leite (Vila Real,PT), I Militao (Vila Real,PT), F Esteves (Vila Real,PT)

H Miranda1 , I Milet2 , N Barros2 , H Leite2 , I Militao2 , F Esteves2 , 1Hospitalar Center Barreiro-Montijo - Lisboa - Portugal , 2Hospital Center of Tras-os-Montes and Alto Douro, Intensive Medicine - Vila Real - Portugal ,



Cardiogenic shock (CS) is a state of critical end-organ hypoperfusion due to primary cardiac dysfunction. Most epidemiological data for CS focus on patients with acute myocardial infarction  managed in intensive care units (ICUs) of cardiology departments.


Identify main predictors of mortality in a general ICU, in the first 24h of cardiogenic shock, and evaluate their impact in the outcome.


Retrospective analysis of patients (P) admitted in our ICU, with confirmed diagnosis of CS, within a period of 5 years (January 2012- December 2016). We analyzed common epidemiological variables, evolution during ICU stay, established therapeutics and outcome.


90 P were included. The mean age of the population was 69,59 ± 12,23 years, with a predominance of males (56,7%). Majority of P coming from the Emergency Room (45,6%) and 26,7% presenting cardiopulmonary arrest at admission. Admission SOFA of 10,39 ± 3,19. The main cause of CS (defined by clinical and echo evaluation) was non-ischemic (66,7%). In 27,8% of P the presence of mixed shock was verified. 68,9% needed mechanical invasive ventilation in the first 24h. Maximum PEEP of 8,22± 2,76 and median weaning of 3 days during ICU stay, respectively. PaO2/FiO2 ratio and lactactes at admission of 178,5 and 2,85, respectively. All the patients needed aminergic support. 34,4% needed renal replacement therapy.

At discharge, the patients presented median ICU stay of 5 days with SOFA, APACHE II and SAPS II of 7.6±5,06, 24,5 and 56,61 ± 19,71, respectively. Hospital mortality of 45,6%.

We found a statistically significant association between outcome and: admission SOFA (p=0,006), APACHE II (p<0,001), etiology (p=0,024) and variation (v) of lactates in the first 24h (p=0,027). We also point out that after applying a logistic regression, only APACHE II (OR: 1,12; IC95%: ,049-1,196) and v24h lactates (OR 0,811; IC95%: 0,672-0,979) had relevant prediction power.


CS requires rapid diagnosis and appropriate therapy to have a positive influence on the outcome. In our study, we found that APACHE II and v24h lactates were the best predictors of mortality.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are